Richardson D, Crossnohere NL, Seo J, et al. - Researchers created an acute myeloid leukemia (AML)-specific discrete choice experiment (DCE) involving multiple stakeholders, to quantify as well as evaluate heterogeneity of the preferences of AML patients for treatment outcomes. Overall, 294 AML patients were included. Event-free survival (EFS), complete remission (CR), time in the hospital, short-term side effects, and long-term side effects were the attributes that were incorporated into the DCE. The most significant offered benefit was a 10% improvement in the likelihood of CR. To obtain a 10% rise in the possibility of CR, the patients were ready to trade up to 22 months of EFS or endure 8.7 months in the hospital or a two-step increment in long-term side effects. The treatments that maximized likelihood at remission were favored by the patients in this national sample of mostly AML survivors, however, findings revealed significant preference heterogeneity for outcomes. The patients' preferences may be influenced by age and gender.